The United States Food and Drug Administration (FDA)—the bedrock of American public health and the global gold standard for medical regulation—finds itself in the throes of a historic institutional crisis. Dr. Marty Makary, who assumed the role of the 27th FDA Commissioner in April 2025, has officially tendered his resignation, bringing an abrupt end to a tenure marked by intense political scrutiny and internal administrative turbulence.
His departure, confirmed following a week of speculation, arrives as the agency struggles to maintain its reputation for scientific independence. According to multiple sources, including reports from the Wall Street Journal, President Donald Trump had been actively considering the termination of Dr. Makary, citing deep-seated dissatisfaction with the agency’s recent regulatory trajectory.
The Catalyst for Departure
The friction between the White House and the FDA Commissioner centered on several high-profile regulatory decisions that triggered public and political debate. Specifically, President Trump was reportedly displeased with the agency’s handling of the authorization of fruit-flavored e-cigarettes and the complex, politically charged landscape surrounding the accessibility of the abortion pill mifepristone.
While the FDA is ostensibly a non-partisan, science-led entity, the current administration’s oversight has blurred the lines between executive mandate and regulatory autonomy. Dr. Makary, who held the position for just over 13 months, leaves behind an agency that is effectively rudderless at the top, with Kyle Diamantas, previously the head of the Food division, stepping in as acting commissioner to bridge the gap.
A Chronology of Instability: 2025–2026
The resignation of Dr. Makary is not an isolated incident; rather, it is the latest chapter in a prolonged narrative of high-level turnover that has crippled the FDA’s leadership structure over the past eighteen months.
The CBER Revolving Door
The Center for Biologics Regulation and Evaluation (CBER) has seen particularly volatile leadership shifts. Dr. Vinay Prasad, a prominent figure in regulatory policy, left the agency in April 2026 for the second time in less than a year. Prasad’s tenure was characterized by ambitious, albeit controversial, efforts to streamline drug approval pathways, specifically the implementation of the "plausible mechanism" framework and the allowance of single clinical trials in lieu of the traditional two-trial standard.
His initial resignation in July 2025 was sparked by internal backlash regarding his "conservative" approach to cell and gene therapy approvals—most notably his regulatory stance on Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) therapy, Elevidys. In a display of the agency’s erratic decision-making, Prasad was reinstated just two weeks after his departure, only to leave again months later.
The CDER Leadership Vacuum
The Center for Drugs Regulation and Evaluation (CDER) has faced similar instability. Dr. Richard Padzur, a seasoned veteran of oncology regulation, departed in December 2025 after serving less than a month in the role. He was subsequently replaced by Dr. Tracy Beth Hoeg, who holds the distinction of being the fifth person to lead the division within a single calendar year. Before Padzur, the post was held by George Tidmarsh, who resigned in November 2025 following an investigation into his personal conduct.
The Conflict with HHS
The broader health apparatus has also suffered from the friction between career scientists and political appointees. Dr. Peter Marks, the former lead of CBER, resigned following an irreparable breakdown in communication with Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. In his parting comments, Marks offered a scathing critique of the current administration, alleging that Secretary Kennedy Jr. did not prioritize "truth and transparency," but rather sought "subservient confirmation of his misinformation and lies."
The Implications: A Regulatory Agency in Peril
The recurring exodus of senior leadership, combined with ongoing accusations of political interference, presents grave implications for the future of American healthcare and the global pharmaceutical market.
Political Politicization and Public Trust
The most significant casualty of this upheaval is the public’s perception of the FDA. Former agency staffers have increasingly gone on the record to voice concerns regarding the "politicization" of regulatory processes. When the public perceives that the FDA’s decisions—whether on vaccines, reproductive health, or e-cigarettes—are being dictated by the political whims of the Oval Office rather than the objective interpretation of clinical data, the agency’s credibility is eroded. This trust deficit has long-term consequences, ranging from vaccine hesitancy to a lack of public confidence in new drug approvals.
Operational Disruption and Drug Review Delays
Beyond the politics, there is a tangible operational crisis. The agency has been grappling with significant drug review delays, which many industry analysts attribute to a combination of mass layoffs and a loss of institutional knowledge. The constant churn of high-level personnel means that projects, regulatory pathways, and inter-departmental collaborations are frequently stalled or abandoned.
When a director of a center like CDER or CBER changes multiple times in a year, the ripple effect on drug sponsors is profound. Companies relying on clear guidance for their pivotal clinical trials are finding themselves in a state of "regulatory limbo," unable to secure the firm commitments necessary to bring life-saving therapies to market.
Supporting Data: The Cost of Churn
While official government data on internal morale is rarely published, the frequency of departures serves as a proxy for institutional health.
- Leadership Turnover: Over the past 16 months, the FDA has seen more than seven high-profile departures or forced resignations.
- The "Acting" Phenomenon: With roles like the FDA Commissioner and various Center heads now being filled by "acting" appointees, the agency lacks the long-term strategic authority necessary to navigate complex public health emergencies.
- Regulatory Backlog: Industry reports indicate that the time-to-approval for certain therapeutic categories has increased by an estimated 15–20% compared to the 2020–2024 period, a trend directly correlated with the staffing instability at the leadership level.
Official Responses and Future Outlook
As of this writing, the White House has maintained a brief stance, characterizing the leadership changes as part of a necessary "strategic realignment" to better serve the American people. However, critics from both sides of the aisle argue that the realignment is, in effect, a dismantling of the agency’s scientific independence.
For the pharmaceutical and medical device industries, the immediate future remains uncertain. The appointment of Kyle Diamantas as acting commissioner is seen as a "placeholder" move, leaving the industry to wonder who—if anyone—will step in to provide the stability required to restore the FDA’s global standing.
The path forward for the FDA requires more than just filling vacancies. It demands a systemic commitment to insulating the agency from executive influence and a return to the evidence-based decision-making that has defined the FDA for over a century. Until the agency can guarantee that its scientists and regulators are free to make decisions based on data alone, the "FDA crisis" will continue to cast a shadow over the future of medical innovation in the United States.
As Dr. Makary exits, the agency is left to grapple with its most profound identity crisis in modern history. Whether it can emerge from this period of turmoil with its integrity intact remains the defining question for the remainder of the current administration.
About the Author
